Molecular diagnostics company Biocartis Group NV (Euronext Brussels:BCART) reported on Tuesday that a new, large prospective study has demonstrated that the Idylla EGFR Mutation Test (CE-IVD2) leads to a significant reduction of time-to-treatment by 48% or on average 16.8 days faster than Next Generation Sequencing (NGS) testing for EGFR positive patients.

This shows Idylla's potential to improve strategic treatment decisions within a multidisciplinary team for patients with advanced non-small cell lung cancer (NSCLC), the company said.

The Idylla platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster, informed treatment decisions.

"Tailoring cancer treatments to individual patients is key, and requires molecular diagnostic testing to help identify the specific biomarkers involved," said Herman Verrelst, CEO of Biocartis

"Integrating decentralised, rapid and easy-to-use Idylla testing in routine use can help broaden access to biomarker testing and as such, improve patient treatment and outcomes."